Despite beneficial outcome in preclinical tumor and metastasis models (Brown et al, 2010; Coxon et al, 2010; Hashizume et al, 2010; Koh et al, 2010; Kienast et al, 2013; Rigamonti et al, 2014), this is to our knowledge the first study that emphasized dual targeting of Ang‐2 and VEGF in GBM. This evidence concerns the gene VEGFA and neoplasm.